Recent Company News

• 03:38 PM ET Jul 02, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 5-Jul

• 10:49 PM ET Jul 01, 2026
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 07:35 PM ET Jul 01, 2026
  

  Otsuka's VOYXACT phase III VISIONARY study shows statistically significant two-year eGFR stabilization (¥10665.0000, 0)

• 11:39 AM ET Jun 29, 2026
  

  China announces preliminary results of 2026 NRDL adjustment, 557 passed for basic medical insurance, 54 passed for commercial insurance list

• 08:04 AM ET Jun 29, 2026
  

  4DMT completes enrollment for 4FRONT-2 global Phase 3 clinical trial of 4D-150 in wet AMD ($11.60, 0.00)

• 02:27 AM ET Jun 25, 2026
  

  Otsuka Holdings' centanafadine XR 280 mg once daily in adults Phase 3b study shows positive topline results for ADHD and comorbid anxiety (¥10870.0000, 0)

• 04:33 AM ET Jun 16, 2026
  

  Otsuka Holdings upgraded to 1-outperform from 2-neutral at SMBC Nikko (¥10360.0000, 0)

• 07:53 PM ET Jun 15, 2026
  

  Sumitomo Pharma reports 'encouraging' new clinical and translational research presented at European Hematology Association (¥1418.5000, 0)

• 02:00 PM ET Jun 15, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 8-Jun

• 08:15 PM ET Jun 14, 2026
  

  Otsuka Holdings completes acquisition of Transcend Therapeutics (¥10250.0000, +50)